Elite Pharma Inc (ELTP) 0.2111 $ELTP
Elite Pharmaceuticals collects record revenues of USD7.1m for Q1 fiscal 2016
M2 - Tue Aug 11, 4:52AM CDT
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) disclosed on Monday that it recorded consolidated revenues of USD7.1m for the quarter ended 30 June 2015, the first quarter of its 2016 fiscal year.
Elite Pharmaceuticals, Inc. Reports Record Revenues for First Quarter of Fiscal Year 2016
GlobeNewswire - Mon Aug 10, 3:20PM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP), announced results for the quarter ended June 30, 2015, the first quarter of its 2016 fiscal year.
Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss 1st Quarter 2016 Financial Results on August 11, 2015
GlobeNewswire - Thu Aug 06, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that its first quarter financial results will be released on Monday, August 10, 2015. Following the announcement, Elite's management will host a live conference call and webcast on Tuesday, August 11 at 11:00 a.m. Eastern Daylight Time to review the company's financial and operating results and provide a general business update. Company executives will conduct a question and answer session following their remarks.
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
GlobeNewswire - Mon Aug 03, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCQB:ELTP), today announced the completion of patient enrollment and dosing for the Phase III efficacy trial for ELI-200, an abuse-deterrent opioid product. This Phase III trial is designed to evaluate the efficacy and safety of abuse deterrent ELI-200 for the treatment of adults with moderate to severe pain following surgery. The study enrolled 163 patients at five clinical sites. Top-line efficacy and safety data from this study are expected to be announced near year's end. Submission of the NDA for ELI-200 is also expected shortly thereafter. "I am very pleased that we have completed enrollment, surgeries and dosing for Elite's Phase III trial for ELI-200," stated Nasrat Hakim, President and Chief Executive Officer of Elite. "We expect the NDA submission for ELI-200 near year's end, and in preparation for an ELI-200 launch in 2016, we are expanding our facility and working with our sales partner, Epic Pharma, on pre-launch activities."
Elite Pharmaceuticals awarded new US patent for abuse deterrent technology
M2 - Wed Jun 17, 4:25AM CDT
Pharmaceutical company Elite Pharmaceutical (OTCBB:ELTP) reported on Tuesday the receipt of the US Patent entitled "Abuse-Resistant Oral Dosage Forms" for its opioid abuse deterrent technology.
Elite Pharmaceutical's (ELTP) CEO Nasrat Hakim on Q4 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Jun 16, 7:50PM CDT
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
GlobeNewswire - Tue Jun 16, 9:33AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced today the issuance of U.S. Patent No. 9,056,054 entitled "Abuse-Resistant Oral Dosage Forms". This patent expands the intellectual property for the Company's opioid abuse deterrent technology. Elite now has four US patents and two Canadian patents issued in this area with additional patents pending in the U.S., Canada and Europe.
Elite Pharmaceuticals posts 9% higher record consolidated revenues for fiscal 2015
M2 - Tue Jun 16, 5:58AM CDT
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) stated on Monday it recorded consolidated revenues of USD5.015m for the fiscal year ended 31 March 2015 (fiscal 2015).
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2015
GlobeNewswire - Mon Jun 15, 3:58PM CDT
Elite Pharmaceuticals Reports Nine Percent Revenue Growth
CORRECTION -- Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss Year End 2015 Financial Results on June 16, 2015
GlobeNewswire - Thu Jun 11, 5:24PM CDT
In the press release issued earlier today by Elite Pharmaceuticals, Inc. (OTCQB:ELTP) with the same headline, please note that the conference call date should be Tuesday, June 16, 2015 and not Tuesday, July 16, 2015 as previously stated in the conference call details. All other information remains the same.
Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss Year End 2015 Financial Results on June 16, 2015
GlobeNewswire - Thu Jun 11, 3:00PM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that its year end financial results will be released on Monday, June 15, 2015. Following the announcement, Elite's management will host a live conference call and webcast on Tuesday, June 16 at 11:00 a.m. Eastern Daylight Time to review the company's financial and operating results and provide a general business update. Company executives will conduct a question and answer session following their remarks.
Elite Pharmaceuticals and Epic Pharma to market abuse-deterrent technology ELI-200
M2 - Wed Jun 10, 4:20AM CDT
Pharmaceutical company Elite Pharmaceuticals (NasdaqGS:ELTP) reported on Tuesday the launch of a sales and distribution licensing agreement for its abuse-deterrent opioid utilising its proprietary pharmacological abuse-deterrent technology, ELI-200, with Epic Pharma.
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
GlobeNewswire - Tue Jun 09, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCQB:ELTP) announced today that it has entered into a sales and distribution licensing agreement with Epic Pharma LLC for ELI-200 (the "License", an abuse-deterrent opioid utilizing Elite's proprietary pharmacological abuse-deterrent technology. Epic will be responsible for sales and marketing of ELI-200, and Elite will be responsible for the manufacture of the product. Epic will pay Elite non-refundable milestone payments totaling $15 million and a royalty based on net product sales. The term of the License is five years and the License is renewable upon mutual agreement at the end of the initial term.
Elite Pharmaceuticals unveils generic Hydroxyzine Tablets
M2 - Wed Apr 22, 6:12AM CDT
Pharmaceutical company Elite Pharmaceuticals (OtherOTC:ELTP) revealed on Tuesday the availability of generic Hydroxyzine HCI 10 mg, 25 mg and 50 mg tablets through Epic Pharma for symptomatic relief of anxiety and tension associated with certain disease states and management of pruritus due to certain allergic conditions.
Elite Pharmaceuticals Announces Launch of Generic Hydroxyzine Tablets
GlobeNewswire - Tue Apr 21, 9:02AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCQB:ELTP) today announced the launch of generic Hydroxyzine HCI 10 mg, 25 mg and 50 mg tablets through Epic Pharma LLC, a private pharmaceutical company located in Laurelton, NY. Hydroxyzine is indicated for symptomatic relief of anxiety and tension associated with certain disease states and management of pruritus due to certain allergic conditions. Annual U.S. sales for immediate release Hydroxyzine HCI 10 mg and 25 mg and 50 mg tablets are approximately $40 million for the twelve months ending June 30, 2014 according to IMS Health Data. Epic will manufacture, package and distribute the product under the Manufacturing and License Agreement previously signed between Epic and Elite.
FDA accepts Teva's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:42AM CST
MNK: 82.08 (-0.92), LCI: 57.14 (+0.52), ACT: 298.98 (-2.94), EGLT: 14.78 (+0.35), ZGNX: 20.04 (-0.56), PFE: 32.97 (+0.35), ABBV: 59.35 (-0.23), TEVA: 63.66 (+1.62), ALKS: 70.95 (+1.28), ACUR: 3.13 (-0.11)
Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q3 2015 - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 18, 2:31PM CST
Elite Pharma set to begin abuse-deterrent opioid Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 9:06PM CST
MNK: 82.08 (-0.92), LCI: 57.14 (+0.52), EGLT: 14.78 (+0.35), ACT: 298.98 (-2.94), ZGNX: 20.04 (-0.56), PFE: 32.97 (+0.35), ABBV: 59.35 (-0.23), TEVA: 63.66 (+1.62), ALKS: 70.95 (+1.28), ACUR: 3.13 (-0.11)
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2015
GlobeNewswire - Tue Feb 17, 4:56PM CST
Revenues Increase 8.5% Over Prior Quarter
Elite Pharmaceuticals Provides Guidance on Phase III Study for ELI-200
GlobeNewswire - Tue Feb 17, 4:55PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCQB:ELTP) announced guidance today regarding the Company's Phase III trial for ELI-200, an abuse deterrent opioid product. Elite has submitted a study protocol to the FDA and dosing for the study is expected to begin shortly after the FDA comments on the protocol are received by Elite. The Company anticipates that it will receive the FDA comments by mid-March and that dosing will take approximately eight weeks to complete.
Elite Pharmaceuticals collects record revenues of USD7.1m for Q1 fiscal 2016
M2 - Tue Aug 11, 4:52AM CDT
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) disclosed on Monday that it recorded consolidated revenues of USD7.1m for the quarter ended 30 June 2015, the first quarter of its 2016 fiscal year.
Elite Pharmaceuticals, Inc. Reports Record Revenues for First Quarter of Fiscal Year 2016
GlobeNewswire - Mon Aug 10, 3:20PM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP), announced results for the quarter ended June 30, 2015, the first quarter of its 2016 fiscal year. Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss 1st Quarter 2016 Financial Results on August 11, 2015
GlobeNewswire - Thu Aug 06, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that its first quarter financial results will be released on Monday, August 10, 2015. Following the announcement, Elite's management will host a live conference call and webcast on Tuesday, August 11 at 11:00 a.m. Eastern Daylight Time to review the company's financial and operating results and provide a general business update. Company executives will conduct a question and answer session following their remarks. Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial
GlobeNewswire - Mon Aug 03, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCQB:ELTP), today announced the completion of patient enrollment and dosing for the Phase III efficacy trial for ELI-200, an abuse-deterrent opioid product. This Phase III trial is designed to evaluate the efficacy and safety of abuse deterrent ELI-200 for the treatment of adults with moderate to severe pain following surgery. The study enrolled 163 patients at five clinical sites. Top-line efficacy and safety data from this study are expected to be announced near year's end. Submission of the NDA for ELI-200 is also expected shortly thereafter. "I am very pleased that we have completed enrollment, surgeries and dosing for Elite's Phase III trial for ELI-200," stated Nasrat Hakim, President and Chief Executive Officer of Elite. "We expect the NDA submission for ELI-200 near year's end, and in preparation for an ELI-200 launch in 2016, we are expanding our facility and working with our sales partner, Epic Pharma, on pre-launch activities." Elite Pharmaceuticals awarded new US patent for abuse deterrent technology
M2 - Wed Jun 17, 4:25AM CDT
Pharmaceutical company Elite Pharmaceutical (OTCBB:ELTP) reported on Tuesday the receipt of the US Patent entitled "Abuse-Resistant Oral Dosage Forms" for its opioid abuse deterrent technology.
Elite Pharmaceutical's (ELTP) CEO Nasrat Hakim on Q4 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Jun 16, 7:50PM CDT
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
GlobeNewswire - Tue Jun 16, 9:33AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) announced today the issuance of U.S. Patent No. 9,056,054 entitled "Abuse-Resistant Oral Dosage Forms". This patent expands the intellectual property for the Company's opioid abuse deterrent technology. Elite now has four US patents and two Canadian patents issued in this area with additional patents pending in the U.S., Canada and Europe. Elite Pharmaceuticals posts 9% higher record consolidated revenues for fiscal 2015
M2 - Tue Jun 16, 5:58AM CDT
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) stated on Monday it recorded consolidated revenues of USD5.015m for the fiscal year ended 31 March 2015 (fiscal 2015).
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2015
GlobeNewswire - Mon Jun 15, 3:58PM CDT
Elite Pharmaceuticals Reports Nine Percent Revenue Growth
CORRECTION -- Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss Year End 2015 Financial Results on June 16, 2015
GlobeNewswire - Thu Jun 11, 5:24PM CDT
In the press release issued earlier today by Elite Pharmaceuticals, Inc. (OTCQB:ELTP) with the same headline, please note that the conference call date should be Tuesday, June 16, 2015 and not Tuesday, July 16, 2015 as previously stated in the conference call details. All other information remains the same.
Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss Year End 2015 Financial Results on June 16, 2015
GlobeNewswire - Thu Jun 11, 3:00PM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that its year end financial results will be released on Monday, June 15, 2015. Following the announcement, Elite's management will host a live conference call and webcast on Tuesday, June 16 at 11:00 a.m. Eastern Daylight Time to review the company's financial and operating results and provide a general business update. Company executives will conduct a question and answer session following their remarks. Elite Pharmaceuticals and Epic Pharma to market abuse-deterrent technology ELI-200
M2 - Wed Jun 10, 4:20AM CDT
Pharmaceutical company Elite Pharmaceuticals (NasdaqGS:ELTP) reported on Tuesday the launch of a sales and distribution licensing agreement for its abuse-deterrent opioid utilising its proprietary pharmacological abuse-deterrent technology, ELI-200, with Epic Pharma.
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200
GlobeNewswire - Tue Jun 09, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCQB:ELTP) announced today that it has entered into a sales and distribution licensing agreement with Epic Pharma LLC for ELI-200 (the "License", an abuse-deterrent opioid utilizing Elite's proprietary pharmacological abuse-deterrent technology. Epic will be responsible for sales and marketing of ELI-200, and Elite will be responsible for the manufacture of the product. Epic will pay Elite non-refundable milestone payments totaling $15 million and a royalty based on net product sales. The term of the License is five years and the License is renewable upon mutual agreement at the end of the initial term. Elite Pharmaceuticals unveils generic Hydroxyzine Tablets
M2 - Wed Apr 22, 6:12AM CDT
Pharmaceutical company Elite Pharmaceuticals (OtherOTC:ELTP) revealed on Tuesday the availability of generic Hydroxyzine HCI 10 mg, 25 mg and 50 mg tablets through Epic Pharma for symptomatic relief of anxiety and tension associated with certain disease states and management of pruritus due to certain allergic conditions.
Elite Pharmaceuticals Announces Launch of Generic Hydroxyzine Tablets
GlobeNewswire - Tue Apr 21, 9:02AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCQB:ELTP) today announced the launch of generic Hydroxyzine HCI 10 mg, 25 mg and 50 mg tablets through Epic Pharma LLC, a private pharmaceutical company located in Laurelton, NY. Hydroxyzine is indicated for symptomatic relief of anxiety and tension associated with certain disease states and management of pruritus due to certain allergic conditions. Annual U.S. sales for immediate release Hydroxyzine HCI 10 mg and 25 mg and 50 mg tablets are approximately $40 million for the twelve months ending June 30, 2014 according to IMS Health Data. Epic will manufacture, package and distribute the product under the Manufacturing and License Agreement previously signed between Epic and Elite. FDA accepts Teva's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:42AM CST
MNK: 82.08 (-0.92), LCI: 57.14 (+0.52), ACT: 298.98 (-2.94), EGLT: 14.78 (+0.35), ZGNX: 20.04 (-0.56), PFE: 32.97 (+0.35), ABBV: 59.35 (-0.23), TEVA: 63.66 (+1.62), ALKS: 70.95 (+1.28), ACUR: 3.13 (-0.11)
Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q3 2015 - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 18, 2:31PM CST
Elite Pharma set to begin abuse-deterrent opioid Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 9:06PM CST
MNK: 82.08 (-0.92), LCI: 57.14 (+0.52), EGLT: 14.78 (+0.35), ACT: 298.98 (-2.94), ZGNX: 20.04 (-0.56), PFE: 32.97 (+0.35), ABBV: 59.35 (-0.23), TEVA: 63.66 (+1.62), ALKS: 70.95 (+1.28), ACUR: 3.13 (-0.11)
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2015
GlobeNewswire - Tue Feb 17, 4:56PM CST
Revenues Increase 8.5% Over Prior Quarter
Elite Pharmaceuticals Provides Guidance on Phase III Study for ELI-200
GlobeNewswire - Tue Feb 17, 4:55PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCQB:ELTP) announced guidance today regarding the Company's Phase III trial for ELI-200, an abuse deterrent opioid product. Elite has submitted a study protocol to the FDA and dosing for the study is expected to begin shortly after the FDA comments on the protocol are received by Elite. The Company anticipates that it will receive the FDA comments by mid-March and that dosing will take approximately eight weeks to complete. 
